Pfizer (PFE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Pfizer Revenue Highlights

Latest Revenue (Y)

$62.58B

Latest Revenue (Q)

$16.65B

Main Segment (Y)

Biopharma Segment

Main Geography (Y)

UNITED STATES

Pfizer Revenue by Period

Pfizer Revenue by Year

Date	Revenue	Change
2025-12-31	$62.58B	-1.65%
2024-12-31	$63.63B	6.84%
2023-12-31	$59.55B	-40.64%
2022-12-31	$100.33B	23.43%
2021-12-31	$81.29B	95.16%
2020-12-31	$41.65B	1.16%
2019-12-31	$41.17B	-23.25%
2018-12-31	$53.65B	2.10%
2017-12-31	$52.55B	-0.53%
2016-12-31	$52.82B	8.13%
2015-12-31	$48.85B	-1.52%
2014-12-31	$49.60B	-3.84%
2013-12-31	$51.58B	-5.62%
2012-12-31	$54.66B	-10.45%
2011-12-31	$61.03B	-8.98%
2010-12-31	$67.06B	34.09%
2009-12-31	$50.01B	3.55%
2008-12-31	$48.30B	-0.27%
2007-12-31	$48.43B	0.12%
2006-12-31	$48.37B	2.04%
2005-12-31	$47.41B	-9.73%
2004-12-31	$52.52B	16.22%
2003-12-31	$45.19B	39.59%
2002-12-31	$32.37B	0.35%
2001-12-31	$32.26B	9.08%
2000-12-31	$29.57B	82.51%
1999-12-31	$16.20B	19.64%
1998-12-31	$13.54B	8.32%
1997-12-31	$12.50B	10.60%
1996-12-31	$11.31B	12.82%
1995-12-31	$10.02B	21.01%
1994-12-31	$8.28B	10.75%
1993-12-31	$7.48B	-

Pfizer generated $62.58B in revenue during NA 2025, up -1.65% compared to the previous quarter, and up 150.25% compared to the same period a year ago.

Pfizer Revenue by Quarter

Date	Revenue	Change
2025-09-28	$16.65B	13.66%
2025-06-29	$14.65B	6.84%
2025-03-29	$13.71B	-22.79%
2024-12-31	$17.76B	0.34%
2024-09-29	$17.70B	33.27%
2024-06-30	$13.28B	-10.73%
2024-03-31	$14.88B	2.12%
2023-12-31	$14.57B	8.00%
2023-10-01	$13.49B	3.72%
2023-07-02	$13.01B	-29.64%
2023-04-02	$18.49B	-23.89%
2022-12-31	$24.29B	7.30%
2022-10-02	$22.64B	-18.40%
2022-07-03	$27.74B	8.11%
2022-04-03	$25.66B	7.65%
2021-12-31	$23.84B	-0.82%
2021-10-03	$24.04B	27.18%
2021-07-04	$18.90B	30.19%
2021-04-04	$14.52B	24.77%
2020-12-31	$11.63B	13.20%
2020-09-27	$10.28B	4.19%
2020-06-28	$9.86B	-2.17%
2020-03-29	$10.08B	-20.53%
2019-12-31	$12.69B	0.06%
2019-09-29	$12.68B	-4.40%
2019-06-30	$13.26B	1.11%
2019-03-31	$13.12B	-6.14%
2018-12-31	$13.98B	5.10%
2018-09-30	$13.30B	-1.25%
2018-07-01	$13.47B	4.34%
2018-04-01	$12.91B	-5.82%
2017-12-31	$13.70B	4.06%
2017-10-01	$13.17B	2.11%
2017-07-02	$12.90B	0.92%
2017-04-02	$12.78B	-6.22%
2016-12-31	$13.63B	4.46%
2016-10-02	$13.04B	-0.78%
2016-07-03	$13.15B	1.09%
2016-04-03	$13.01B	-7.42%
2015-12-31	$14.05B	16.22%
2015-09-27	$12.09B	1.97%
2015-06-28	$11.85B	9.10%
2015-03-29	$10.86B	-17.18%
2014-12-31	$13.12B	6.12%
2014-09-28	$12.36B	-3.23%
2014-06-29	$12.77B	12.51%
2014-03-30	$11.35B	-16.26%
2013-12-31	$13.56B	7.24%
2013-09-29	$12.64B	-2.54%
2013-06-30	$12.97B	-3.90%
2013-03-31	$13.50B	-10.41%
2012-12-31	$15.07B	7.81%
2012-09-30	$13.98B	0.06%
2012-07-01	$13.97B	0.89%
2012-04-01	$13.85B	-17.32%
2011-12-31	$16.75B	0.82%
2011-10-02	$16.61B	0.75%
2011-07-03	$16.48B	2.88%
2011-04-03	$16.02B	-8.75%
2010-12-31	$17.56B	9.79%
2010-10-03	$15.99B	-6.64%
2010-07-04	$17.13B	3.35%
2010-04-04	$16.58B	0.24%
2009-12-31	$16.54B	42.30%
2009-09-27	$11.62B	5.80%
2009-06-28	$10.98B	1.08%
2009-03-29	$10.87B	-11.98%
2008-12-31	$12.35B	3.12%
2008-09-28	$11.97B	-1.29%
2008-06-29	$12.13B	2.37%
2008-03-30	$11.85B	-7.94%
2007-12-31	$12.87B	-

Pfizer generated $16.65B in revenue during Q3 2025, up 13.66% compared to the previous quarter, and up 125.38% compared to the same period a year ago.

Pfizer Revenue Breakdown

Pfizer Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Biopharma Segment	$61.20B	$62.40B	$7.58B	$98.99B	-
Total Alliance Biopharmaceuticals	-	-	-	$8.54B	$7.65B
Comirnaty	-	-	-	$3.10B	-
Total Sterile Injectable Pharmaceuticals	-	-	-	-	$5.75B
Total Biosimilars	-	-	-	-	$2.34B

Pfizer's latest annual revenue breakdown by segment (product or service), as of Dec 25: Biopharma Segment (100.00%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Oct 23	Jul 23	Apr 23	Dec 22	Oct 22	Jul 22	Apr 22	Dec 21	Oct 21	Jul 21	Apr 21	Sep 20
Biopharma Segment	$30.58B	$16.31B	$14.30B	$17.41B	$17.39B	$2.07B	$2.17B	$13.87B	$12.93B	$1.72B	-	-	-	-	-	-	-	-	-	-
Comirnaty	-	-	-	-	-	-	-	-	$140.00M	$300.00M	$1.70B	$600.00M	$68.00M	$800.00M	-	-	-	-	-	-
Total Alliance Biopharmaceuticals	-	-	-	-	-	-	-	-	-	$1.97B	$1.69B	$2.32B	$2.31B	$1.93B	$2.07B	$1.88B	$1.77B	-	-	-
Total Sterile Injectable Pharmaceuticals	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.29B	$1.33B	$1.44B	$1.44B	$1.38B	$1.48B	-
Total Biosimilars	-	-	-	-	-	-	-	-	-	-	-	-	-	$580.00M	$605.00M	$680.00M	$575.00M	$559.00M	$530.00M	-
Upjohn Segment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$76.00M
Biopharma, Upjohn And Consumer Healthcare Segments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.13B

Pfizer's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Biopharma Segment (100.00%).

Pfizer Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Emerging Markets	$9.31B	$8.88B	$12.00B	$20.10B	-
Developed Rest Of World	$16.19B	$16.06B	$7.76B	$15.78B	-
UNITED STATES	$37.08B	$38.69B	$27.09B	$42.47B	$29.75B
Developed Europe	-	-	$11.65B	$21.98B	-

Pfizer's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (59.25%), Developed Rest Of World (25.87%), and Emerging Markets (14.88%).

Quarterly Revenue by Country

Country	Dec 25	Sep 25	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Oct 23	Jul 23	Apr 23	Oct 22	Jul 22	Apr 22	Dec 21	Oct 21	Jul 21	Apr 21	Dec 20	Sep 20
UNITED STATES	$17.49B	$10.69B	$8.89B	$9.22B	$12.06B	$7.89B	$9.51B	$4.59B	$7.80B	$6.18B	$8.51B	$13.85B	$11.22B	$8.92B	$7.48B	$7.08B	$7.59B	$7.60B	$4.94B	$5.72B
Developed Rest Of World	$9.10B	$3.70B	$3.39B	$6.28B	$3.41B	$3.16B	$3.20B	$2.91B	$1.07B	-	-	-	-	-	-	-	-	-	-	-
Emerging Markets	$4.68B	$2.27B	$2.37B	$2.26B	$2.23B	$2.23B	$2.17B	$2.31B	$2.37B	-	-	-	-	-	-	-	-	-	-	-
Developed Europe	-	-	-	-	-	-	-	$4.43B	$1.98B	-	-	-	-	-	-	-	-	-	-	-

Pfizer's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (55.94%), Developed Rest Of World (29.10%), and Emerging Markets (14.97%).

Pfizer Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
NVO	Novo Nordisk	$232.26B	$65.35B
MRK	Merck	$65.01B	$17.28B
PFE	Pfizer	$62.58B	$16.65B
BMY	Bristol-Myers Squibb	$48.19B	$12.22B
SNY	Sanofi	$43.07B	$11.12B
AMGN	Amgen	$36.75B	$9.56B
GSK	GSK	$30.33B	$7.36B
GILD	Gilead Sciences	$29.44B	$7.77B
SYK	Stryker	$25.12B	$6.06B
DHR	Danaher	$24.57B	$6.05B
BSX	Boston Scientific	$20.07B	$5.07B

PFE Revenue FAQ

What is Pfizer’s yearly revenue?

Pfizer's yearly revenue for 2025 was $62.58B, representing a decrease of -1.65% compared to 2024. The company's yearly revenue for 2024 was $63.63B, representing an increase of 6.84% compared to 2023. PFE's yearly revenue for 2023 was $59.55B, representing a decrease of -40.64% compared to 2022.

What is Pfizer’s quarterly revenue?

Pfizer's quarterly revenue for Q3 2025 was $16.65B, a 13.66% increase from the previous quarter (Q2 2025), and a -5.92% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $14.65B, a 6.84% increase from the previous quarter (Q1 2025), and a 10.31% increase year-over-year (Q2 2024). PFE's quarterly revenue for Q1 2025 was $13.72B, a -22.79% decrease from the previous quarter (Q4 2024), and a -7.82% decrease year-over-year (Q1 2024).

What is Pfizer’s revenue growth rate?

Pfizer's revenue growth rate for the last 3 years (2023-2025) was 5.08%, and for the last 5 years (2021-2025) was -23.02%.

What are Pfizer’s revenue streams?

Pfizer's revenue streams in c 25 are Biopharma Segment

What is Pfizer’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Pfizer was Biopharma Segment. This segment made a revenue of $61.2B, representing 100.00% of the company's total revenue.